Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CAMKK1 | Q8N5S9 | 5/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620627 | 0.93 | PTGDR (0.55) | KDM4EGLAPTGDRPTGDR2CAMKK2 | |
| SCHEMBL23243079 | 0.85 | KDM4E (0.52) | KDM4EGLAPTGDRPTGDR2MEN1 | |
| SCHEMBL15567556 | 0.80 | NR4A2 (0.47) | KDM4EGLAPTGDRPTGDR2MAPT | |
| SCHEMBL29655541 | 0.79 | CA12 (0.53) | CAMKK2MAPTPOLBCAMKK1 | |
| SCHEMBL29154739 | 0.79 | KDM4E (0.46) | KDM4ECAMKK2MAPTPOLBCAMKK1 | |
| SCHEMBL28170365 | 0.79 | KDM4E (0.46) | KDM4ECAMKK2MAPTPOLBCAMKK1 | |
| SCHEMBL27642034 | 0.78 | KDM4E (0.41) | KDM4EGLAPTGDRPTGDR2POLB | |
| SCHEMBL16421197 | 0.78 | CSNK2A1 (0.48) | PTGDR2CAMKK2MEN1KMT2AMAPT | |
| SCHEMBL30410929 | 0.78 | CSNK2A1 (0.48) | PTGDR2CAMKK2MEN1KMT2AMAPT | |
| SCHEMBL16836614 | 0.78 | KEAP1 (0.47) | PTGDR2CAMKK2CAMKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648851-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | Astrazeneca AB (SE) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025149498-A1 | BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024149728-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024149728-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | WO | disclosed |
| CN-115003673-B | Dihydropyrimidine compound, preparation method and application thereof | 上海维申医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115003673-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114621219-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| WO-2019238067-A1 | PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2019-12-19 | — | — | WO | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | KDM4E 2769/4885GLA 1422/4885PTGDR 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.